News >

Future Looks Bright for CAR T-Cell Therapies in Hematologic Malignancies

Brandon Scalea
Published: Wednesday, May 08, 2019

Nirav N. Shah, MD

Nirav N. Shah, MD

CD19-directed CAR T-cell therapy has demonstrated impressive responses in select patients with refractory hematologic malignancies, and ongoing research may further increase the durability of this clinical activity, said Nirav N. Shah, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x